Michel Goedert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4892248/publications.pdf

Version: 2024-02-01

219 papers	49,481 citations	2203 99 h-index	2116 203 g-index
249 all docs	249 docs citations	249 times ranked	30208 citing authors

#	Article	IF	Citations
1	Cryo-EM structures of amyloid-Î² 42 filaments from human brains. Science, 2022, 375, 167-172.	6.0	228
2	Classification of diseases with accumulation of Tau protein. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	32
3	A tribute to John Q. Trojanowski (1946â€“2022), neuropathologist extraordinaire. Brain Pathology, 2022, 32, e13066.	2.1	1
4	Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature, 2022, 605, 310-314.	13.7	88
5	Assembly of recombinant tau into filaments identical to those of Alzheimerâ€™s disease and chronic traumatic encephalopathy. ELife, 2022, 11, .	2.8	121
6	Seeded assembly inÂvitro does not replicate the structures of Î±â€synuclein filaments from multiple system atrophy. FEBS Open Bio, 2021, 11, 999-1013.	1.0	95
7	Cryo-EM structures of tau filaments from Alzheimerâ€™s disease with PET ligand APN-1607. Acta Neuropathologica, 2021, 141, 697-708.	3.9	99
8	Synthesis and Assessment of Novel Probes for Imaging Tau Pathology in Transgenic Mouse and Rat Models. ACS Chemical Neuroscience, 2021, 12, 1885-1893.	1.7	8
9	Structure-based classification of tauopathies. Nature, 2021, 598, 359-363.	13.7	409
10	Tau Protein and Frontotemporal Dementias. Advances in Experimental Medicine and Biology, 2021, 1281, 177-199.	0.8	8
11	Cryo-EM structures of Ï„ filaments from human brain. Essays in Biochemistry, 2021, 65, 949-959.	2.1	15
12	Assembly of Î±-synuclein and neurodegeneration in the central nervous system of heterozygousÂM83 mice following the peripheral administration of Î±-synuclein seeds. Acta Neuropathologica Communications, 2021, 9, 189.	2.4	10
13	Editorial overview: Neurobiology of disease. Current Opinion in Neurobiology, 2020, 61, iii-iv.	2.0	0
14	Tau proteinopathies and the prion concept. Progress in Molecular Biology and Translational Science, 2020, 175, 239-259.	0.9	20
15	Structures of Î±-synuclein filaments from multiple system atrophy. Nature, 2020, 585, 464-469.	13.7	446
16	Î±-Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species. Journal of Biological Chemistry, 2020, 295, 6652-6664.	1.6	23
17	Novel tau filament fold in corticobasal degeneration. Nature, 2020, 580, 283-287.	13.7	381
18	Cryo-EM structures of tau filaments. Current Opinion in Structural Biology, 2020, 64, 17-25.	2.6	165

#	Article	IF	Citations
19	Dextran sulphate-induced tau assemblies cause endogenous tau aggregation and propagation in wild-type mice. Brain Communications, 2020, 2, fcaa091.	1.5	6
20	Inhibition of synucleinopathic seeding by rationally designed inhibitors. ELife, 2020, 9, .	2.8	54
21	Heparin-induced tau filaments are polymorphic and differ from those in Alzheimerâ€™s and Pickâ€™s diseases. ELife, 2019, 8, .	2.8	309
22	Silver staining (Campbell-Switzer) of neuronal Î±-synuclein assemblies induced by multiple system atrophy and Parkinsonâ€™s disease brain extracts in transgenic mice. Acta Neuropathologica Communications, 2019, 7, 148.	2.4	28
23	Cerebrospinal fluid from Alzheimerâ€™s disease patients promotes tau aggregation in transgenic mice. Acta Neuropathologica Communications, 2019, 7, 72.	2.4	16
24	Aaron Klug and the study of Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 859-861.	0.4	0
25	Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature, 2019, 568, 420-423.	13.7	528
26	Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord. Acta Neuropathologica Communications, 2019, 7, 44.	2.4	23
27	Luminescent conjugated oligothiophenes distinguish between Î±-synuclein assemblies of Parkinsonâ€™s disease and multiple system atrophy. Acta Neuropathologica Communications, 2019, 7, 193.	2.4	35
28	Ordered Assembly of Tau Protein and Neurodegeneration. Advances in Experimental Medicine and Biology, 2019, 1184, 3-21.	0.8	42
29	Galectin-8â€“mediated selective autophagy protects against seeded tau aggregation. Journal of Biological Chemistry, 2018, 293, 2438-2451.	1.6	84
30	Measurement of Tau Filament Fragmentation Provides Insights into Prion-like Spreading. ACS Chemical Neuroscience, 2018, 9, 1276-1282.	1.7	68
31	Parkinson's disease â€” the story of an eponym. Nature Reviews Neurology, 2018, 14, 57-62.	4.9	35
32	Neurodegeneration and the ordered assembly of Î±-synuclein. Cell and Tissue Research, 2018, 373, 137-148.	1.5	79
33	Distinct Conformers of Assembled Tau in Alzheimer's and Pick's Diseases. Cold Spring Harbor Symposia on Quantitative Biology, 2018, 83, 163-171.	2.0	53
34	Tau filaments from multiple cases of sporadic and inherited Alzheimerâ€™s disease adopt a common fold. Acta Neuropathologica, 2018, 136, 699-708.	3.9	252
35	Rodent models for Alzheimer disease. Nature Reviews Neuroscience, 2018, 19, 583-598.	4.9	240
36	Structures of filaments from Pickâ€™s disease reveal a novel tau protein fold. Nature, 2018, 561, 137-140.	13.7	625

#	Article	IF	Citations
37	Tau filaments in neurodegenerative diseases. FEBS Letters, 2018, 592, 2383-2391.	1.3	100
38	Ubiquitination of alpha-synuclein filaments by Nedd4 ligases. PLoS ONE, 2018, 13, e0200763.	1.1	27
39	Tau Filaments and the Development of Positron Emission Tomography Tracers. Frontiers in Neurology, 2018, 9, 70.	1.1	27
40	Beta-sheet assembly of Tau and neurodegeneration in Drosophila melanogaster. Neurobiology of Aging, 2018, 72, 98-105.	1.5	24
41	Neurodegeneration and the Ordered Assembly of Tau. , 2018, , 81-98.		0
42	Propagation of Tau aggregates. Molecular Brain, 2017, 10, 18.	1.3	154
43	The Transcellular Propagation and Intracellular Trafficking of Î±-Synuclein. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024380.	2.9	28
44	Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 574-579.	3.3	143
45	The Prion-Like Behavior of Assembled Tau in Transgenic Mice. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024372.	2.9	28
46	Propagation of Tau Aggregates and Neurodegeneration. Annual Review of Neuroscience, 2017, 40, 189-210.	5.0	453
47	[ECâ€03â€“02]: CRYOâ€EM STRUCTURES OF TAU FILAMENTS FROM ALZHEIMER'S DISEASE BRAIN. Alzheimer's and Dementia, 2017, 13, P892.	0.4	3
48	Cryo-EM structures of tau filaments from Alzheimerâ€™s disease. Nature, 2017, 547, 185-190.	13.7	1,502
49	Like prions: the propagation of aggregated tau and Î±-synuclein in neurodegeneration. Brain, 2017, 140, 266-278.	3.7	248
50	The Synucleinopathies: Twenty Years On. Journal of Parkinson's Disease, 2017, 7, S51-S69.	1.5	350
51	What is the evidence that tau pathology spreads through prion-like propagation?. Acta Neuropathologica Communications, 2017, 5, 99.	2.4	272
52	P3-065: Transection of Targeted Axonal Pathways Inhibits Network Spread of Tau Pathology in a P301S Model of TAU Propagation. , 2016, 12, P842-P842.		0
53	O4â€04â€02: Characterisation of Tau Species Involved in Tau Seeding and Spread in Cellular and Animal Models. Alzheimer's and Dementia, 2016, 12, P340.	0.4	0
54	The ordered assembly of tau is the gainâ€ofâ€toxic function that causes human tauopathies. Alzheimer's and Dementia, 2016, 12, 1040-1050.	0.4	54

#	Article	IF	Citations
55	Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau. Journal of Neuroscience, 2016, 36, 762-772.	1.7	129
56	Why has therapy development for dementia failed in the last two decades?. Alzheimer's and Dementia, 2016, 12, 60-64.	0.4	194
57	Distinct Spacing Between Anionic Groups: An Essential Chemical Determinant for Achieving Thiopheneâ€Based Ligands to Distinguish Î²â€Amyloid or Tau Polymorphic Aggregates. Chemistry - A European Journal, 2015, 21, 9072-9082.	1.7	44
58	Frontispiece: Distinct Spacing Between Anionic Groups: An Essential Chemical Determinant for Achieving Thiopheneâ€Based Ligands to Distinguish Î²â€Amyloid or Tau Polymorphic Aggregates. Chemistry - A European Journal, 2015, 21, .	1.7	0
59	The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Frontiers in Neuroscience, 2015, 9, 184.	1.4	34
60	Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates. Journal of Biological Chemistry, 2015, 290, 1049-1065.	1.6	225
61	Invited review: Frontotemporal dementia caused by microtubuleâ€associated protein tau gene (<scp>MAPT</scp>) mutations: a chameleon for neuropathology and neuroimaging. Neuropathology and Applied Neurobiology, 2015, 41, 24-46.	1.8	360
62	PART is part of Alzheimer disease. Acta Neuropathologica, 2015, 129, 749-756.	3.9	256
63	Alzheimerâ€™s and Parkinsonâ€™s diseases: The prion concept in relation to assembled AÎ², tau, and Î±-synuclein. Science, 2015, 349, 1255555.	6.0	753
64	Crystals of a toxic core. Nature, 2015, 525, 458-459.	13.7	6
65	Invited review: Prionâ€like transmission and spreading of tau pathology. Neuropathology and Applied Neurobiology, 2015, 41, 47-58.	1.8	130
66	Piericidin A Aggravates Tau Pathology in P301S Transgenic Mice. PLoS ONE, 2014, 9, e113557.	1.1	15
67	Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathologica, 2014, 127, 299-301.	3.9	116
68	A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathologica, 2014, 127, 667-683.	3.9	390
69	Anti-amyloid Compounds Inhibit Î±-Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA). Journal of Biological Chemistry, 2014, 289, 11897-11905.	1.6	83
70	Prion-like Mechanisms in the Pathogenesis of Tauopathies and Synucleinopathies. Current Neurology and Neuroscience Reports, 2014, 14, 495.	2.0	111
71	Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1527-1538.	1.8	38
72	P3-049: CHARACTERISATION OF A CO-CULTURE CELL-BASED MODEL OF TAU AGGREGATION AND PROPAGATION. , 2014, 10, P646-P646.		0

#	Article	IF	Citations
73	Tau Silencing by siRNA in the P301S Mouse Model of Tauopathy. Current Gene Therapy, 2014, 14, 343-351.	0.9	44
74	Circadian clocks and neurodegenerative diseases: time to aggregate?. Current Opinion in Neurobiology, 2013, 23, 880-887.	2.0	93
75	Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice. Acta Neuropathologica Communications, 2013, 1, 82.	2.4	43
76	Parkinson's Disease â€“ the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	1.5	79
77	The Structure of Crossâ€Î² Tapes and Tubes Formed by an Octapeptide, Î±SÎ²1. Angewandte Chemie - International Edition, 2013, 52, 2279-2283.	7.2	46
78	100 years of Lewy pathology. Nature Reviews Neurology, 2013, 9, 13-24.	4.9	939
79	O1-07-04: Rapid and progressive neurofibrillary tangle pathology in a novel in vivo model of tau propagation: Pattern of spread is determined by structural connectivity not spatial proximity. , 2013, 9, P141-P142.		0
80	Prion-Like Properties of Assembled Tau Protein. Research and Perspectives in Alzheimer's Disease, 2013, , 87-95.	0.1	1
81	Tau pathology and neurodegeneration. Lancet Neurology, The, 2013, 12, 609-622.	4.9	893
82	â€œPrionâ€Likeâ€•Templated Misfolding in Tauopathies. Brain Pathology, 2013, 23, 342-349.	2.1	114
83	The Structural Basis for Optimal Performance of Oligothiopheneâ€Based Fluorescent Amyloid Ligands: Conformational Flexibility is Essential for Spectral Assignment of a Diversity of Protein Aggregates. Chemistry - A European Journal, 2013, 19, 10179-10192.	1.7	95
84	Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9535-9540.	3.3	648
85	Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice. PLoS ONE, 2013, 8, e62459.	1.1	196
86	Frontotemporal Dementia: Implications for Understanding Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006254-a006254.	2.9	127
87	Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain, 2012, 135, 2169-2177.	3.7	291
88	Stimulation of autophagy is neuroprotective in a mouse model of human tauopathy. Autophagy, 2012, 8, 1686-1687.	4.3	83
89	Reduced Axonal Transport and Increased Excitotoxic Retinal Ganglion Cell Degeneration in Mice Transgenic for Human Mutant P301S Tau. PLoS ONE, 2012, 7, e34724.	1.1	56
90	Synucleinopathies and Tauopathies. , 2012, , 829-843.		5

#	Article	IF	Citations
91	Phosphorylation of microtubuleâ€associated protein tau by AMPKâ€related kinases. Journal of Neurochemistry, 2012, 120, 165-176.	2.1	59
92	Long-Term In Vivo Imaging of Fibrillar Tau in the Retina of P301S Transgenic Mice. PLoS ONE, 2012, 7, e53547.	1.1	148
93	Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability. Neurobiology of Aging, 2011, 32, 419-433.	1.5	108
94	S1-02-01: Prion-like properties of tau. , 2011, 7, S86-S86.		0
95	Pathogenesis of the Tauopathies. Journal of Molecular Neuroscience, 2011, 45, 425-431.	1.1	107
96	Cell-Mediated Neuroprotection in a Mouse Model of Human Tauopathy. Journal of Neuroscience, 2010, 30, 9973-9983.	1.7	106
97	Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7969-7974.	3.3	65
98	Human Î²-Synuclein Rendered Fibrillogenic by Designed Mutations. Journal of Biological Chemistry, 2010, 285, 38555-38567.	1.6	15
99	The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends in Neurosciences, 2010, 33, 317-325.	4.2	402
100	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinsonâ€™s disease. Brain, 2010, 133, 2032-2044.	3.7	236
101	Inhibition of Î±â€synuclein fibril assembly by small molecules: Analysis using epitopeâ€specific antibodies. FEBS Letters, 2009, 583, 787-791.	1.3	39
102	Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biology, 2009, 11, 909-913.	4.6	1,515
103	The value of incomplete mouse models of Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 70-74.	3.3	79
104	In vitro high affinity Î±â€synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain¹. Journal of Neurochemistry, 2008, 105, 1428-1437.	2.1	84
105	Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)â€1â€fluoroâ€2,5â€bis(3â€hydroxycarbonylâ€4â€hydroxy)styrylbenzene]. FEBS Letters, 2008, 582, 901-906.	1.3	38
106	Analysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy. American Journal of Pathology, 2008, 172, 123-131.	1.9	113
107	The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain, 2008, 131, 72-89.	3.7	98
108	Oskar Fischer and the study of dementia. Brain, 2008, 132, 1102-1111.	3.7	90

#	Article	IF	Citations
109	White Matter Tauopathy With Globular Glial Inclusions: A Distinct Sporadic Frontotemporal Lobar Degeneration. Journal of Neuropathology and Experimental Neurology, 2008, 67, 963-975.	0.9	111
110	Chapter 4 Tau Protein and the Dementias. Blue Books of Neurology, 2007, , 88-111.	0.1	0
111	Sequence Determinants for Amyloid Fibrillogenesis of Human Î±-Synuclein. Journal of Molecular Biology, 2007, 374, 454-464.	2.0	66
112	Phosphorylation of human microtubule-associated protein tau by protein kinases of the AGC subfamily. FEBS Letters, 2007, 581, 2657-2662.	1.3	24
113	Alois Alzheimer: His Life and Times. Brain Pathology, 2007, 17, 57-62.	2.1	44
114	A simple algorithm locates Î²-strands in the amyloid fibril core of Î±-synuclein, AÎ², and tau using the amino acid sequence alone. Protein Science, 2007, 16, 906-918.	3.1	101
115	The novel Tau mutation G335S: clinical, neuropathological and molecular characterization. Acta Neuropathologica, 2007, 113, 461-470.	3.9	34
116	Cell-Cycle Markers in a Transgenic Mouse Model of Human Tauopathy. American Journal of Pathology, 2006, 168, 878-887.	1.9	35
117	Small Molecule Inhibitors of Î±-Synuclein Filament Assemblyâ€. Biochemistry, 2006, 45, 6085-6094.	1.2	348
118	Synuclein Proteins of the Pufferfish Fugu rubripes:â€‰ Sequences and Functional Characterization. Biochemistry, 2006, 45, 2599-2607.	1.2	21
119	Cysteine misincorporation in bacterially expressed human Î±-synuclein. FEBS Letters, 2006, 580, 1775-1779.	1.3	74
120	Tau protein, the paired helical filament and Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 195-207.	1.2	181
121	Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38? or JNK2 in the presence of heparin generates the AT100 epitope. Journal of Neurochemistry, 2006, 99, 154-164.	2.1	68
122	A Century of Alzheimer's Disease. Science, 2006, 314, 777-781.	6.0	1,798
123	Frontotemporal lobar degeneration through loss of progranulin function. Brain, 2006, 129, 2808-2810.	3.7	22
124	Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human Â-Synuclein(1-120): Implications for Lewy Body Disorders. Journal of Neuroscience, 2006, 26, 3942-3950.	1.7	302
125	The Alzheimer tangle â€" 100 years on.. , 2006, , 297-304.		4
126	Tau gene mutations and their effects. Movement Disorders, 2005, 20, S45-S52.	2.2	115

#	Article	IF	Citations
127	Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the Î±-synuclein gene. Acta Neuropathologica, 2005, 110, 298-305.	3.9	59
128	Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38Î´ at Thr50 promotes microtubule assembly. Journal of Cell Science, 2005, 118, 397-408.	1.2	120
129	Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins. Journal of Biological Chemistry, 2005, 280, 7614-7623.	1.6	479
130	Mutations causing neurodegenerative tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 240-250.	1.8	347
131	Earlyâ€onset Dementia with Lewy Bodies. Brain Pathology, 2004, 14, 137-147.	2.1	26
132	Mutation E46K increases phospholipid binding and assembly into filaments of human Î±-synuclein. FEBS Letters, 2004, 576, 363-368.	1.3	241
133	Tau protein and neurodegeneration. Seminars in Cell and Developmental Biology, 2004, 15, 45-49.	2.3	140
134	Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein. American Journal of Pathology, 2004, 165, 1643-1652.	1.9	180
135	Stress- and mitogen-induced phosphorylation of the synapse-associated protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2. Biochemical Journal, 2004, 380, 19-30.	1.7	92
136	Î±-Synuclein and Neurodegeneration. , 2004, , 204-IX.		0
137	Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO Journal, 2003, 22, 70-77.	3.5	299
138	Variable phenotypic expression and extensive tau pathology in two families with the noveltau mutation L315R. Annals of Neurology, 2003, 54, 573-581.	2.8	82
139	Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-Â structure. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9034-9038.	3.3	281
140	Neurodegenerative tauopathy in the worm. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9653-9655.	3.3	7
141	The neurobiology of the tauopathies. , 2003, , 245-261.		0
142	Functional Characterization of FTDP-17 tau Gene Mutations through Their Effects on Xenopus Oocyte Maturation. Journal of Biological Chemistry, 2002, 277, 9199-9205.	1.6	44
143	Biophysical Properties of the Synucleins and Their Propensities to Fibrillate. Journal of Biological Chemistry, 2002, 277, 11970-11978.	1.6	413
144	Molecular Cloning and Functional Characterization of Chicken Brain Tau:Â Isoforms with up to Five Tandem Repeatsâ€. Biochemistry, 2002, 41, 15203-15211.	1.2	49

#	Article	IF	Citations
145	Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Letters, 2002, 515, 151-154.	1.3	65
146	Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein. Journal of Neuroscience, 2002, 22, 9340-9351.	1.7	643
147	A noveltau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. Annals of Neurology, 2002, 51, 373-376.	2.8	91
148	A Raman optical activity study of rheomorphism in caseins, synucleins and tau. FEBS Journal, 2002, 269, 148-156.	0.2	214
149	Functional effects of tau gene mutations DeltaN296 and N296H. Journal of Neurochemistry, 2002, 80, 548-551.	2.1	57
150	Reduced Binding of Protein Phosphatase 2A to Tau Protein with Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Mutations. Journal of Neurochemistry, 2002, 75, 2155-2162.	2.1	87
151	Proteasomal degradation of tau protein. Journal of Neurochemistry, 2002, 83, 176-185.	2.1	302
152	Neurodegenerative Tauopathies. Annual Review of Neuroscience, 2001, 24, 1121-1159.	5.0	2,416
153	Regulation of Alternative Splicing of Human Tau Exon 10 by Phosphorylation of Splicing Factors. Molecular and Cellular Neurosciences, 2001, 18, 80-90.	1.0	101
154	The significance of tau and Î±-synuclein inclusions in neurodegenerative diseases. Current Opinion in Genetics and Development, 2001, 11, 343-351.	1.5	89
155	The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2BÉ› at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochemical Journal, 2001, 355, 609-615.	1.7	299
156	Pick's disease associated with the novelTau gene mutation K369I. Annals of Neurology, 2001, 50, 503-513.	2.8	128
157	Alpha-synuclein and neurodegenerative diseases. Nature Reviews Neuroscience, 2001, 2, 492-501.	4.9	1,249
158	Parkinsons Disease and other Î±-Synucleinopathies. Clinical Chemistry and Laboratory Medicine, 2001, 39, 308-12.	1.4	89
159	From genetics to pathology: tau and aâ€“synuclein assemblies in neurodegenerative diseases. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 213-227.	1.8	58
160	Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy as Î±-Synucleinopathies. , 2001, 62, 33-59.		19
161	Tau Gene Mutations and Tau Pathology in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17. Advances in Experimental Medicine and Biology, 2001, 487, 21-37.	0.8	14
162	Tau mutations altering splicing of tau exon 10 in japanese frontotemporal dementia. , 2001, , 81-84.		0

#	Article	IF	Citations
163	TauGene Mutation K257T Causes a Tauopathy Similar to Pick's Disease. Journal of Neuropathology and Experimental Neurology, 2000, 59, 990-1001.	0.9	145
164	Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochemical Journal, 2000, 352, 145-154.	1.7	171
165	A panel of epitope-specific antibodies detects protein domains distributed throughout human ?-synuclein in lewy bodies of Parkinson's disease. , 2000, 59, 528-533.		197
166	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Annals of Neurology, 2000, 47, 422-429.	2.8	109
167	A noveltau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-943.	2.8	136
168	Characterisation of isolated Î±-synuclein filaments from substantia nigra of Parkinson's disease brain. Neuroscience Letters, 2000, 292, 128-130.	1.0	157
169	Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 110-121.	1.8	127
170	The natural osmolyte trimethylamineN-oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly. FEBS Letters, 2000, 484, 265-270.	1.3	42
171	The Î±â€Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy. Annals of the New York Academy of Sciences, 2000, 920, 16-27.	1.8	437
172	Progress in Hereditary Tauopathies: A Mutation in the Tau Gene (G389R) Causes a Pick Diseaseâ€like Syndrome. Annals of the New York Academy of Sciences, 2000, 920, 52-62.	1.8	30
173	Tau Gene Mutations in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDPâ€17): Their Relevance for Understanding the Neurogenerative Process. Annals of the New York Academy of Sciences, 2000, 920, 74-83.	1.8	54
174	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). , 2000, 47, 422.		6
175	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-43.	2.8	40
176	Tau Pathology in a Family with Dementia and a P301L Mutation in Tau. Journal of Neuropathology and Experimental Neurology, 1999, 58, 335-345.	0.9	170
177	Phosphorylation of cytosolic phospholipase A2 in platelets is mediated by multiple stress-activated protein kinase pathways. FEBS Journal, 1999, 265, 195-203.	0.2	63
178	Pinning down phosphorylated tau. Nature, 1999, 399, 739-740.	13.7	13
179	Effect of SBâ€‰203580 on the activity of c-Raf in vitro and in vivo. Oncogene, 1999, 18, 2047-2054.	2.6	143
180	High Prevalence of Mutations in the Microtubule-Associated Protein Tau in a Population Study of Frontotemporal Dementia in the Netherlands. American Journal of Human Genetics, 1999, 64, 414-421.	2.6	410

#	Article	IF	Citations
181	Epitope mapping of LB509, a monoclonal antibody directed against human Î±-synuclein. Neuroscience Letters, 1999, 269, 13-16.	1.0	96
182	Tau protein and the paired helical filament of Alzheimerâ€™s disease. Brain Research Bulletin, 1999, 50, 469-470.	1.4	20
183	FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. FEBS Letters, 1999, 443, 93-96.	1.3	188
184	Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Letters, 1999, 450, 306-311.	1.3	231
185	Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Letters, 1999, 451, 191-196.	1.3	106
186	A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of Axin and Î²-catenin. FEBS Letters, 1999, 458, 247-251.	1.3	212
187	Alternative splicing of synaptotagmins involving transmembrane exon skipping. FEBS Letters, 1999, 460, 417-422.	1.3	37
188	Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 1101-1118.	1.8	165
189	The Tauopathies. American Journal of Pathology, 1999, 154, 1-6.	1.9	54
190	Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. Journal of Neuropathology and Experimental Neurology, 1999, 58, 667-677.	0.9	381
191	TauGene Mutation G389R Causes a Tauopathy with Abundant Pick Body-like Inclusions and Axonal Deposits. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1207-1226.	0.9	206
192	Tau protein pathology in neurodegenerative diseases. Trends in Neurosciences, 1998, 21, 428-433.	4.2	652
193	Filamentous Î±-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters, 1998, 251, 205-208.	1.0	941
194	Filamentous nerve cell inclusions in neurodegenerative diseases. Current Opinion in Neurobiology, 1998, 8, 619-632.	2.0	247
195	Tau Mutations Cause Frontotemporal Dementias. Neuron, 1998, 21, 955-958.	3.8	294
196	Effect of heparin on phosphorylation site specificity of neuronal Cdc2-like kinase. FEBS Letters, 1998, 423, 227-230.	1.3	17
197	Synthetic filaments assembled from C-terminally truncated Î±-synuclein. FEBS Letters, 1998, 436, 309-312.	1.3	373
198	Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Letters, 1998, 437, 207-210.	1.3	440

#	Article	IF	Citations
199	Binding of Î±-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson's Disease Mutation. Journal of Biological Chemistry, 1998, 273, 26292-26294.	1.6	464
200	Chapter 21 Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Progress in Brain Research, 1998, 117, 287-306.	0.9	64
201	Alzheimer-like Changes in Microtubule-associated Protein Tau Induced by Sulfated Glycosaminoglycans. Journal of Biological Chemistry, 1997, 272, 33118-33124.	1.6	184
202	13 Activation of the novel MAP kinase homologue SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6). Biochemical Society Transactions, 1997, 25, S569-S569.	1.6	8
203	Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Letters, 1997, 409, 57-62.	1.3	272
204	SKK4, a novel activator of stress-activated protein kinase-1 (SAPK1/JNK). FEBS Letters, 1997, 414, 153-158.	1.3	50
205	Examination of the role of endopeptidase 3.4.24.15 in AÎ² secretion by human transfected cells. British Journal of Pharmacology, 1997, 121, 556-562.	2.7	37
206	The awakening of Î±-synuclein. Nature, 1997, 388, 232-233.	13.7	94
207	Î±-Synuclein in Lewy bodies. Nature, 1997, 388, 839-840.	13.7	7,181
208	SAP kinase-3, a new member of the family of mammalian stress-activated protein kinases. FEBS Letters, 1996, 383, 273-276.	1.3	146
209	Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochemical Journal, 1996, 316, 655-660.	1.7	136
210	Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau. Journal of Biological Chemistry, 1995, 270, 18917-18922.	1.6	319
211	ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neuroscience Letters, 1995, 192, 209-212.	1.0	56
212	Glycogen synthase kinase-3Î² phosphorylates tau protein at multiple sites in intact cells. Neuroscience Letters, 1995, 197, 149-153.	1.0	205
213	Synaptotagmin V: a novel synaptotagmin isoform expressed in rat brain. FEBS Letters, 1995, 361, 196-200.	1.3	66
214	Risky apolipoprotein in brain. Nature, 1994, 372, 45-46.	13.7	62
215	Identification of two distinct synucleins from human brain. FEBS Letters, 1994, 345, 27-32.	1.3	922
216	Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends in Neurosciences, 1993, 16, 460-465.	4.2	644

#	Article	IF	Citations
217	Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron, 1993, 10, 1089-1099.	3.8	845
218	p42 map kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1Implications for Alzheimer's disease. FEBS Letters, 1992, 312, 95-99.	1.3	269
219	The Repeat Region of Microtubule-Associated Protein Tau Forms Part of the Core of the Paired Helical Filament of Alzheimer's Disease. Annals of Medicine, 1989, 21, 127-132.	1.5	98